OBJECTIVE: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics. METHOD: Baseline audit against evidence-based standards, followed by provision of benchmarked data and a range of change interventions, with re-audit 1 year later. RESULTS: At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re-audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re-audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia. CONCLUSION: The programme's success may be partly attributed to the use of a widely-accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams.
OBJECTIVE: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatricpatients prescribed antipsychotics. METHOD: Baseline audit against evidence-based standards, followed by provision of benchmarked data and a range of change interventions, with re-audit 1 year later. RESULTS: At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re-audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re-audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia. CONCLUSION: The programme's success may be partly attributed to the use of a widely-accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams.
Authors: Robert O Cotes; Alex de Nesnera; Michael Kelly; Karen Orsini; Haiyi Xie; Greg McHugo; Stephen Bartels; Mary F Brunette Journal: Community Ment Health J Date: 2015-02-03
Authors: Susanne H Stanley; Jonathan D E Laugharne; Stephen Addis; Diane Sherwood Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2012-07-04 Impact factor: 4.328
Authors: W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff Journal: Schizophr Bull Date: 2014-04 Impact factor: 9.306
Authors: Julie Kreyenbuhl; Lisa B Dixon; Clayton H Brown; Deborah R Medoff; Elizabeth A Klingaman; Li Juan Fang; Stephanie Tapscott; Mary Brighid Walsh Journal: Community Ment Health J Date: 2016-04-09
Authors: Lisa M Ruiz; Mackenzie Damron; Kyle B Jones; Dean Weedon; Paul S Carbone; Amanda V Bakian; Deborah A Bilder Journal: J Autism Dev Disord Date: 2016-06
Authors: Julia B Baller; Emma E McGinty; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit Journal: BMC Psychiatry Date: 2015-03-21 Impact factor: 3.630